(RTTNews) - MaxCyte, Inc. (MXCT) has entered into a definitive agreement to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management for total consideration of $151.8 million. At the close of the transaction, MaxCyte will pay $105.0 million in cash, subject
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.